Corn Oil
drugOn this page
Also known as unhydrogenatedMaydolVegetable oilcornZea mays oil
Summary
Corn Oil (CHEMBL2108243) is a phase-3 clinical-stage unknown; indicated across 9 conditions including atherosclerosis and hypertriglyceridemia.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 9 conditions
- Clinical trials: 27
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108243 |
| Name | Corn Oil |
| Type | Unknown |
| Max phase | 3 |
Also known as: Corn oil, unhydrogenated, Maydol, Vegetable oil, corn, Zea mays oil, CORN OIL
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
9 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atherosclerosis | 3 | MONDO:0005311 | EFO:0003914 |
| hypertriglyceridemia | 3 | MONDO:0005347 | EFO:0004211 |
| chronic kidney disease | 3 | MONDO:0005300 | EFO:0003884 |
| depressive disorder | 3 | MONDO:0002050 | MONDO:0002050 |
| obesity disorder | 2 | MONDO:0011122 | EFO:0001073 |
| epilepsy | 2 | MONDO:0005027 | EFO:0000474 |
| major depressive disorder | 2 | MONDO:0002009 | MONDO:0002009 |
| myocardial infarction | 1 | MONDO:0005068 | EFO:0000612 |
| asthma | 1 | MONDO:0004979 | MONDO:0004979 |
Clinical trials
Total trials: 27.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 16 |
| PHASE3 | 4 |
| PHASE2 | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE4 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06129526 | PHASE4 | UNKNOWN | Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes |
| NCT00116857 | PHASE3 | COMPLETED | Omega-3 Fatty Acids to Improve Depression and Reduce Cardiovascular Risk Factors |
| NCT01422317 | PHASE3 | COMPLETED | Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction |
| NCT01744275 | PHASE2/PHASE3 | SUSPENDED | HOPE-Epilepsy Trial |
| NCT02625870 | PHASE3 | UNKNOWN | Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides |
| NCT03280615 | PHASE3 | COMPLETED | Omega 3 Fatty Acids in Patients With Chronic Renal Disease |
| NCT00312897 | PHASE2 | COMPLETED | Omega-3 Fatty Acids in Adolescent Depression |
| NCT00806442 | PHASE1/PHASE2 | COMPLETED | Treatment of Bronchial Asthma With Borage and Echium Seed Oils |
| NCT00962598 | PHASE2 | COMPLETED | The Role Of Omega-3 Fatty Acids In Adolescent Depression |
| NCT01145066 | PHASE2 | COMPLETED | Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects |
| NCT01191177 | PHASE1/PHASE2 | WITHDRAWN | Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease |
| NCT05404230 | Not specified | RECRUITING | Prevention of Oxaliplatin-induced Nerve Damage in the Body’s Extremities |
| NCT07514663 | Not specified | RECRUITING | Assessing the Effects of Corn and Avocado Oils on the Cardiometabolic Risk Factor Profile |
| NCT00571948 | Not specified | COMPLETED | Modification in Complementary Food Composition to Improve the Status of Iron and Fatty Acids in Infants. |
| NCT00680355 | Not specified | COMPLETED | Bioavailability of Golden Rice Carotenoids in Humans |
| NCT00794079 | Not specified | COMPLETED | Omega-3 Fatty Acids and Muscle Protein Synthesis |
| NCT00891826 | Not specified | COMPLETED | Omega-3 Fatty Acids in Bipolar Patients With a Low Omega-3 Index and Reduced Heart Rate Variability |
| NCT01308957 | Not specified | COMPLETED | Fish Oil and Muscle Function |
| NCT01634776 | Not specified | COMPLETED | Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans |
| NCT01806142 | Not specified | COMPLETED | Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome |
| NCT01841944 | Not specified | COMPLETED | Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction |
| NCT01925716 | Not specified | COMPLETED | Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids |
| NCT02006394 | Not specified | COMPLETED | Novel Dietary Interventions for Treating Insulin Resistance |
| NCT02173587 | Not specified | UNKNOWN | Study Evaluating the Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis |
| NCT02346994 | Not specified | COMPLETED | Development of Melt Organic Baking Fat for Reducing Child Obesity |
| NCT03202654 | Not specified | COMPLETED | Effects of Corn and Coconut Oils on Lipoprotein Lipids, Insulin Sensitivity and Inflammation |
| NCT06061510 | Not specified | COMPLETED | Fish Oil-derived Omega-3 Fatty Acids on Gut Microbiota and Lipid Metabolome in Type 2 Diabetes Mellitus |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).